Amicogen, Inc. (KOSDAQ:092040)

Market Cap	132.45B -28.6%
Revenue (ttm)	41.98B -75.8%
Net Income	-29.96B
EPS	-542.79
Shares Out	70.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,198,838
Average Volume	767,096
Open	1,804.00
Previous Close	1,803.00
Day's Range	1,701.00 - 1,926.00
52-Week Range	1,160.00 - 4,980.00
Beta	n/a
RSI	57.82
Earnings Date	May 21, 2026

About Amicogen

Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company offers specialty enzymes, including CX, SP, etc. for pharmaceutical, food, chemical, and energy industries. It also provides new bio-ingredients, such as N-acetylglucosamine for skin moisturizing and joint health; pinitol/D-chiro-inositol; collagen peptide and collagen tripeptide for skin and health; chitoslim and chitosan oligosaccharides; and lactic acid bacteria, as well as fucoxanthin, curezyme, food enzyme, and bamboo salt. In add...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 092040

Financial Performance

In 2025, Amicogen's revenue was 41.98 billion, a decrease of -75.82% compared to the previous year's 173.60 billion. Losses were -29.96 billion, -43.25% less than in 2024.